Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL389132 | 0.90 | GPR119 (0.66) | GPR119CYP2C9RAB9A | |
| SCHEMBL27747805 | 0.90 | GPR119 (0.49) | GPR119CYP2C9PIK3CDMETKDR | |
| SCHEMBL5140735 | 0.87 | CYP2C9 (0.44) | GPR119CYP2C9METKDRMAPK14 | |
| SCHEMBL3169529 | 0.85 | GPR119 (0.52) | GPR119CYP2C9RAB9AMETKDR | |
| SCHEMBL390219 | 0.85 | GPR119 (0.66) | GPR119CYP2C9RAB9A | |
| SCHEMBL27755093 | 0.84 | GPR119 (0.53) | GPR119CYP2C9PIK3CD | |
| SCHEMBL1897239 | 0.82 | GPR119 (0.67) | GPR119CYP2C9 | |
| SCHEMBL27734763 | 0.80 | GPR119 (0.60) | GPR119CYP2C9PIK3CD | |
| SCHEMBL389599 | 0.80 | GPR119 (0.64) | GPR119CYP2C9 | |
| SCHEMBL1071546 | 0.80 | GPR119 (0.56) | GPR119CYP2C9PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101332303-A | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level | ARENA PHARM INC (US) | 2008-12-31 | — | — | CN | disclosed |